Registry for assessing the HyperArc procedure for brain metastases treatment
HyperArc Registry Study
Varian, a Siemens Healthineers Company · NCT05270707
This study is testing how well the HyperArc treatment works for people with brain metastases compared to other options they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Varian, a Siemens Healthineers Company (industry) |
| Locations | 5 sites (Birmingham, Alabama and 4 other locations) |
| Trial ID | NCT05270707 on ClinicalTrials.gov |
What this trial studies
The HyperArc registry collects data to evaluate the effectiveness of the HyperArc stereotactic radiosurgery (SRS) procedure for treating brain metastases. This observational study aims to compare HyperArc's efficacy against alternative treatment options. By utilizing advanced technology and streamlined workflows, HyperArc seeks to improve patient safety and treatment efficiency. Participants include patients who have received or are scheduled to receive treatment with HyperArc, allowing for comprehensive data collection on outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults who have received or are scheduled to receive treatment using the HyperArc method.
Not a fit: Patients who do not meet the inclusion criteria for HyperArc treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of HyperArc, potentially leading to improved treatment options for patients with brain metastases.
How similar studies have performed: While this registry approach is common, the specific application of HyperArc in this context is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Received or scheduled to receive treatment using the HyperArc treatment method * Age of legal adult according to local law * Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board Exclusion Criteria: * None, apart from not meeting Inclusion Criteria
Where this trial is running
Birmingham, Alabama and 4 other locations
- University of Alabama — Birmingham, Alabama, United States (RECRUITING)
- Icon Cancer Centre Canberra — Bruce, Australian Capital Territory, Australia (NOT_YET_RECRUITING)
- Icon Cancer Centre Greenslopes — Greenslopes, Queensland, Australia (RECRUITING)
- Icon Cancer Centre Maroochydore — Maroochydore, Queensland, Australia (RECRUITING)
- Icon Cancer Centre Gold Coast Private — Southport, Queensland, Australia (RECRUITING)
Study contacts
- Study coordinator: Lawrence MacDonald, PhD
- Email: HyperArcRegistry@varian.com
- Phone: 2066129290
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial, Stereotactic Radiosurgery